Result: Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS
Involved:
Published:
Freiburg : Universität, 2024
Scope:
1 Online-Ressource
Format:
Language:
English
Notes:
The oncologist. - 29, 7 (2024) , 581-588, ISSN: 1549-490X
DOI:
10.1093/oncolo/oyae019